Literature DB >> 3346822

A system approach to pharmacodynamics. I: Theoretical framework.

P Veng-Pedersen1, W R Gillespie.   

Abstract

A general theoretical framework is constructed for the relationship between a pharmacokinetic response r (e.g., systemic drug concentration or input rate), and an observed pharmacologic effect response E. The overall relationship may be described mathematically by E = omega(r) = omega p(omega b(omega r(r))) where omega is an operator that describes the overall relationship, and omega r, omega b, and omega p are operators that describe the contributions of components of the pharmacodynamic system. The kinetic basis for applying certain general mathematical properties such as linearity are discussed. The result is the introduction of various specific mathematical structures that may be applied to pharmacodynamic systems [e.g., E = phi t(r), E = phi t(psi r*r), E = phi p(psi p*phi b(r)), and E = phi p(psi p*phi b(psi r*r))].

Mesh:

Substances:

Year:  1988        PMID: 3346822     DOI: 10.1002/jps.2600770108

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  12 in total

Review 1.  Noncompartmental versus compartmental modelling in clinical pharmacokinetics.

Authors:  W R Gillespie
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

Review 2.  Systems dynamics in clinical pharmacokinetics. An introduction.

Authors:  J M van Rossum; J E de Bie
Journal:  Clin Pharmacokinet       Date:  1989-07       Impact factor: 6.447

3.  Estimation of amobarbital plasma-effect site equilibration kinetics. Relevance of polyexponential conductance functions.

Authors:  J W Mandema; P Veng-Pedersen; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1991-12

Review 4.  The use of kinetic-dynamic interactions in the evaluation of drugs.

Authors:  D B Campbell
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

5.  Bioavailability assessment from pharmacologic data: method and clinical evaluation.

Authors:  G Stagni; A M Shepherd; Y Liu; W R Gillespie
Journal:  J Pharmacokinet Biopharm       Date:  1997-06

6.  New mathematical implementation of generalized pharmacodynamic models: method and clinical evaluation.

Authors:  G Stagni; A M Shepherd; Y Liu; W R Gillespie
Journal:  J Pharmacokinet Biopharm       Date:  1997-06

7.  A 'bottom-up' approach for endo-PK/PD analysis.

Authors:  S Neelakantan; J A Widness; R L Schmidt; P Veng-Pedersen
Journal:  Biopharm Drug Dispos       Date:  2006-10       Impact factor: 1.627

8.  Linear and nonlinear system approaches in pharmacokinetics: how much do they have to offer? II. The response mapping operator (RMO) approach.

Authors:  P Veng-Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1988-10

9.  Linear and nonlinear system approaches in pharmacokinetics: how much do they have to offer? I. General considerations.

Authors:  P Veng-Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1988-08

10.  Validation of a variable direction hysteresis minimization pharmacodynamic approach: cardiovascular effects of alfentanil.

Authors:  N B Modi; P Veng-Pedersen
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.